[{"orgOrder":0,"company":"Cryoport Systems Inc","sponsor":"Syneos Health","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Cryoport Systems Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Cryoport Systems Inc \/ Syneos Health","highestDevelopmentStatusID":"3","companyTruncated":"Cryoport Systems Inc \/ Syneos Health"}]

Find Clinical Drug Pipeline Developments & Deals by Cryoport Systems Inc

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The partnership will support the global advancement of cell and gene therapies.The new partnership couples the full suite of clinical development services offered by Syneos Health with IntegriCell™, Cryoport's platform.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 18, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Syneos Health

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank